Pathogenetic aspects of hypolipidemic drugs antimicrobial potential in metabolic syndrome therapy: a theoretical study
DOI:
https://doi.org/10.24959/ubphj.17.128Keywords:
metabolic syndrome, antimicrobial activity, dyslipidemiaAbstract
Topicality. Metabolic syndrome (MS) is an extremely common medical and social problem. However, there is no modern understanding of the MS ethiopathogenetic mechanisms. Debates about MS discuss different versions of the development of this symptom complex, when each of the clusters can be primary in the pathogenesis of MS. Therefore, any metabolic processes disorders in the human body are always accompanied with and lead to a changes in quantitative and qualitative microbiocenoses composition, and vice versa, microbiota imbalance may induce the development of pathological states including MS.
Aim. To analyze the published data that concern antimicrobial potential of modern drugs with lipid-lowering properties used in complex therapy of MS.
Materials and methods. Lipid-lowering agents and their direct or indirect antimicrobial effect may cause the microbiota imbalance in the human body. While studying the data, we analyzed antimicrobial potential of modern drugs with lipid-lowering properties used in complex therapy of MS. We studied recent research in the field of microecology and the results of significant effect in normal microflora on metabolic processes.
Results and discussion. According to modern concepts, an important pathogenetic link in the obesity and MS development is the imbalance in normal intestinal microflora. At the same time, lipid-lowering agents can have a direct or indirect antimicrobial effect and, consequently, cause an imbalance of microbiota in the human body. Thereby, it is important for the therapy effectiveness to take into account the significant antimicrobial potential of drugs used in the correction of metabolic disorders.
Conclusions. The future complex antimicrobial properties study of drugs used in the correction of described pathological states has a good perspective.
References
Cameron, A. J., Shaw, J. E., Zimmet, P. Z. (2004). The metabolic syndrome: prevalence in worldwide populations. Endocrinology and Metabolism Clinics of North America, 33 (2), 351–375. doi: 10.1016/j.ecl.2004.03.005
Wang, G. R., Li, L., Pan, Y. H. et al. (2013). Prevalence of metabolic syndrome among urban community residents in China. BMC Public Health, 13 (1), 599. doi: 10.1186/1471–2458–13–599
Van Vliet–Ostaptchouk, J. V., Nuotio, M–L., Slagter, S. N. et al. (2014). The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC endocrine disorders, 14 (1), 9. doi: 10.1186/1472–6823–14–9
Sergeev, V. V. (2009). Vrach, 2, 36–41.
Villamor, E., Finan, C. C., Ramirez–Zea, M., Roman, A. V. (2016). Prevalence and sociodemographic correlates of metabolic syndrome in school–aged children and their parents in nine Mesoamerican countries. Public Health Nutrition, 20 (2), 255–265.
Grundy, S. M. (2016). Metabolic syndrome update. Trends in cardiovascular medicine, 26 (4), 364–373.
Kaur, J. (2014) A comprehensive review on metabolic syndrome. Cardiology research and practice, 1–21. doi: 10.1155/2014/943162
Grundy, S. M., Cleeman, J. I., Daniels, S. R. et al. (2005). Diagnosis and management of the metabolic syndrome. Circulation, 112 (17), 2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404
Day, C. (2005). Diagnostic definitions—metabolic syndrome. The British Journal of Diabetes. Vascular Disease, 5 (3), 115–118. doi: 10.1177/14746514050050030101
Guo, S. (2014). Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. Journal of Endocrinology, 220 (2), T1–T23. doi: 10.1530/JOE–13–0327
Roitberg, G. E., Ushakova, T. I., Dorosh, Zh. V. (2004). Kardiologiia, 3, 94–101.
Reaven, G. M. (2007). The individual components of the metabolic syndrome: is there a raison d’Еtre? J.Am.Coll. Nutr., 26, 3, 191–195. doi: 10.1080/07315724.2007.10719601
Chazova, I. E., Mychka, V. B. (2008). Metabolicheskii sindrom. Мoscow: Меdia Меdika, 319.
Ginzburg, М. М., Koriukov, N. N. (2002). Ozhirenie. Vliianie na razvitie metabolicheskogo sindroma. Profilaktika i lechenie. Мoscow: Меdpraktika, 23–25.
Ikewaki, K., Tohyama, J. (2004). Dyslipidemia in metabolic syndrome. Nihon rinsho. Japanese journal of clinical medicine, 62 (6), 1099–1103.
Devi, S. (2017). Dyslipidemia in Metabolic Syndrome: an Overview of Lipoprotein– Related Disorders. International Journal of Cardiology and Lipidology Research, 4 (1). doi: 10.15379/2410–2822.2017.04.01.02
Chibisov, S. M., Rapoport, S. I., Kolesnikov, D. B. et al. (2008). Klinicheskaia меditcina, 6, 30–35.
Grundy, S. M. (2016). Metabolic syndrome update. Trends in cardiovascular medicine, 26 (4), 364–373. doi: 10.1016/j.tcm.2015.10.004
Shenderov, B. A. (2011). Probiotics and functional foods. Food Engineering. [Eds UNESCO–EOLSS Joint Committee], in Encyclopedia of Life Support Systems (EOLSS). Oxford,UK: Developed under the Auspices of the UNESCO, EOLSS Publishers.
Topping, D. L., Clifton, P. M. (2001). Shot–chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiological reviews, 81 (3), 1031–1064.
Parfenov, А. I., Chernin, V. V., Bondarenko, V. M. et al. (2014). Russkii meditcinskii zhurnal, 22 (15), 1088–1092.
Wilson, I.D., Nicholson, J. K. (2017). Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Translational Research, 179, 204–222. doi: 10.1016/j.trsl.2016.08.002
DeGruttola, A. K., Low, D., Mizoguchi, A., Mizoguchi, E. (2016). Current understanding of dysbiosis in disease in human and animal models. Inflammatory bowel diseases, 22 (5), 1137. doi: 10.1097/MIB.0000000000000750
Velikaia, M. M., Sheveleva, N. E. (2010). Ukrainskyi biofarmatsevtychnyi zhurnal – Ukrainian biopharmaceutical journal, 4 (9), 6 – 12.
Ghose, T. (2016). Statins in Dyslipidemia: handbook of Lipidology, 105.
Тvorogova, М. G., Samoilenko, Е. Yu., Naumov, V. G. (2008). Laboratornaia meditcina, 9, 7–11.
Baranova, N. А., Kreier, V. G., Osmolovskii, А. А. et al. (2010). Immunopatologiia, allergologiia, infektologiia, 1, 240–240.
Hennessy, E., Adams, C., Reen, F.J., O’Gara, F. (2016). Is there potential for repurposing statins as novel antimicrobials? Antimicrobial Agents and Chemotherapy, 60 (9), 5111–5121. doi: 10.1128/AAC.00192–16
Dutta, N. K., Bruiners, N., Pinn, M. L. et al. (2016). Statin adjunctive therapy shortens the duration of TB treatment in mice. Journal of Antimicrobial Chemotherapy, 71 (6), 1570–1577. doi: 10.1093/jac/dkw014
Wong, R. P., Davis, T. M. (2012). In vitro antimalarial activity and drug interactions of fenofibric acid. Antimicrobial agents and chemotherapy, 56 (6), 2814–2818. doi: 10.1128/AAC.05076–11
Madhosingh, C., Orr, W. (1981). Antimicrobial effects of clofibrate on the wheat pathogen Fusarium culmorum. Journal of Environmental Science & Health Part B, 16 (5), 587–604. doi: 10.1080/03601238109372281
Out, C., Groen, A.K., Brufau, G. (2012). Bile acid sequestrants: more than simple resins. Current opinion in lipidology, 23 (1), 43–55. doi: 10.1097/MOL.0b013e32834f0ef3
Lukasova, M., Malaval, C., Gille, A. et al. (2011). Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest., 121 (3), 1163–1173. doi: 10.1172/JCI41651
Kurmangulov, А. А., Dorodneva, E. F., Isakova, D. N. (2016). Ozhirenie i metabolism, 1, 16–19.
Festi, D., Schiumerini, R., Eusebi, L. H. et al. (2014). Gut microbiota and metabolic syndrome. World J Gastroenterol, 20 (43), 16079–16094. doi: 10.3748/wjg.v20.i43.16079
Zakharenko, S. M., Fominykh, Yu. A., Mekhtiev, S. N. (2011). Effektivnaia farmakoterapiia, 7, 14–22.
Sina, C., Gavrilova, O., Förster, M. et al. (2009). G protein–coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. The Journal of Immunology, 183 (11), 7514–7522. doi: 10.4049/jimmunol.0900063
Kimura, I., Inoue, D., Maeda, T., Hara, T., Ichimura, A., Miyauchi, S., Tsujimoto, G. (2011). Short–chain fatty acids and ketones directly regulate sympathetic nervous system via G protein–coupled receptor 41 (GPR41). Proceedings of the National Academy of Sciences, 108 (19), 8030–8035. doi: 10.1073/pnas.1016088108
Wostmann, B. S. (1973). Intestinal bile acids and cholesterol absorption in the germfree rat. J. Nutr., 103 (7), 982– 990.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
